Indivior PLC
INDV
查看详细走势图
34.360USD
-0.090-0.26%
收盘 02/06, 16:00（美东）报价延迟15分钟
4.29B总市值
34.93市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.26%
5天
-2.88%
1月
-5.06%
6月
+56.18%
今年开始到现在
-4.24%
1年
+222.63%
查看详细走势图
TradingKey Indivior PLC股票评分
单位: USD 更新时间: 2026-02-06操作建议
Indivior PLC当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名63/159位。机构持股占比非常低，近一月多位分析师给出公司评级为买入。最高目标价45.57。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Indivior PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Indivior PLC亮点
亮点风险
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
业绩高增长
公司营业收入稳步增长，连续3年增长31.85%
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值34.93，处于3年历史高位
Hotchkis & Wiley持仓
明星投资者Hotchkis & Wiley持仓，最新持仓市值1.48K
分析师目标
根据
7
位分析师
买入
评级
45.571
目标均价
+31.18%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Indivior PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Indivior PLC简介
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
公司代码INDV
公司Indivior PLC
CEOCiaffoni (Joseph J)
网址https://www.indivior.com/en
相关品种
